Arena Pharmaceuticals, Inc.'s ( ARNA ) share price has entered into oversold territory with an RSI value of 28.73. The Zacks Consensus Estimate on Arena Pharmaceuticals, Inc.'s earnings for the full year period has loss by 0.01 cents over the past two months to $-0.14 per share. Currently, Arena Pharmaceuticals, Inc. is a Zacks #2 Rank ("Buy"), suggesting that now might be a good time to get in on ( ARNA ) after its recent drop.
that was referring to recent drop...
Read more on Nasdaq
Daniel, I will take your post of a RSI of 28.73 (a very important technical indicator) over these calculus mathematics where folks are trying to figure out profits on so many bottles if this happens, blah, blah, blah. Thanks for bringing this to our attention.
Zach's just released this an hour ago.
Arena Pharmaceuticals, Inc. (ARNA) was a big mover last session, as the company saw its shares rise by over 17% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend of the company, as the stock is now trading above the volatile price range of $4.08 to $4.75 in the past one-month time frame.
The company has seen no estimate revisions over the past one month and the Zacks Consensus Estimate has remained unchanged over the same timeframe. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Arena Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Zach's ranks everything #1 (best) through #5 (worst).
A #2 ranking does not mean that they rank it the second best stock in the universe. It means it's among their second tier of attractive stocks.